Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Toxicity of Escalating Doses of Adoptively Infused ex Vivo Selected CD56+CD3- NK Cells on Day 7 Following Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies.

NCT01336478 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT01336478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01336478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Toxicity of Escalating Doses of Adoptively Infused ex Vivo Selected CD56+CD3- NK Cells on Day 7 Following Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies.
Lead sponsor
Imperial College London
Phase
Phase 1
Overall status
Withdrawn
Start date
April 30, 2011
Completion date
June 30, 2014
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic stem cell transplant, cd56+cd3- nk cells, haematological malignancies